Each month the FormsNet3 team makes updates to validations, question enabling/disabling and form generation.
The monthly maintenance updates are tentatively scheduled for the 4th Friday of the month.
August 2024 (released August 23rd, 2024)
No updates to communicate.
July 2024 (released July 26th, 2024)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F4100 r9 | Q4 & 5-11 | Validation (Modify) | Q4 is disabled and Q5-11 are enabled | Q4 is enabled, Q5-11 are disabled | Align with changes to infusion reporting workflow. |
| F2100 r9 | Q3 & 4-9 | Validation (Modify) | Q3 is disabled and Q4-9 are enabled | Q3 is enabled and Q4-9 are disabled | Align with changes to infusion reporting workflow. |
| F2100 r9 | Q275, 279, 355 | Validation (Add) | No current validation for Q275. Q279 must be answered. No current validation for Q355. |
If visit is greater than or equal to 2Y, then Q275 cannot be equal to VOD/SOS option. If visit is equal to 100D, 6M or 1Y, then Q279 must be answered. If visit is greater than or equal to 2Y, then Q355 cannot be equal to hemorrhagic cystitis/hematuria. |
Necessary for certain organ impairments to be disabled after the 1Y reporting period. |
| F2100 r9 | Validation (Modify) | If Q257 contains any (BR_OBLIT, COP_BOOP, DAH, OTH_NONINF_PULM), then Q264 must be answered. If and only if Q272 = yes, then Q277 must be answered. If and only if Q319 = yes, then Q333 must be answered. If and only if Q344 = pancreatitis, then Q350 must be answered. |
If Q257 contains any (BR_OBLIT, COP_BOOP, OTH_NONINF_PULM), then Q264 must be answered. If and only if Q275 = any VOD, medication toxicity, other toxicity, or unknown etiology, then Q277 must be answered. If and only if Q322 = hyperlipidemia, then Q333 must be answered. Q350 must not be answered. |
Burden reduction. Some organ impairments do not require a resolution date. | |
| F2400 r10 | Q12 | Validation (Modify) | If and only if Q44 = any, or infusion type = allo, then Q12 must be answered | If and only if Q44 = any, then Q12 must be answered for first allo HCT and disabled for subsequent infusions | Burden reduction. |
| F2400 r10 | Q77 | Validation (Modify) | If and only if Q44 = auto, then Q77 must be answered | Q77 is disabled for gene therapy infusions | Reduce duplicate reporting, as Q77 is now collected on F2003r2 (Gene Therapy Product Form). |
June 2024 (released June 21, 2024)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2018 r6 | Q83 | Validation (Modify) | Q83 must be equal to F2402 Q401 | Q83 must be equal to F2402 Q400 | Correction to validation |
| F2402 r7 | Validation (Modify) | If and only if Q91 is equal to any, then Q93 must be answered | If date received is not answered or is greater than 2024-01-26 and Q91 is equal to any, then Q93 must be answered If date received is less than or equal to 2024-01-26 and Q91 is equal to any, then Q93 is optional |
Validations updated so that when edits are made to F2402s completed prior to January 2024 release, no errors will populate on unanswered MRD questions | |
| If and only if Q167 is equal to any, then Q169 must be answered | If date received is not answered or is greater than 2024-01-26 and Q167 is equal to any, then Q169 must be answered If date received is less than or equal to 2024-01-26 and Q167 is equal to any, then Q169 is optional |
||||
| F2402 r8 | Q217 | Validation (Add) | If Q195 is equal to any, then Q217 must be answered | If Q195 is equal to any, then Q217 must be answered (additional subtypes added) | Data quality improvement |
May 2024 (released May 17, 2024)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F4100 r9 | Q148 | Validation (Modify) | If latest track for CT event = 15 year follow-up or standard follow-up CRF, then Q148 must be answered | If latest track for CT event = 15 year follow-up or standard follow-up CRF AND treatment path for current event = CT, then Q148 must be answered | Burden reduction, Q148 will only be answered if the combined follow-up event is a CT |
April 2024 (released April 19, 2024)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2100 r9 | Q245-249 | Validation (Modify) | Covid-19 vaccine questions must be answered | Questions disabled | Burden reduction, no longer collecting data |
| F2400 r10 | Q87-94 | Validation (Modify) | Covid-19 infection and vaccine questions must be answered | Questions disabled | |
| Q95 | Modify (Floating Text) | Is there a history of mechanical ventilation (excluding COVID-19 (SARS-CoV-2))? | Is there a history of mechanical ventilation? | ||
| F2450 r7 | Q49-55 | Validation (Modify) | Covid-19 infection and vaccine questions must be answered | Questions disabled | |
| F4000 r10 | Q81-90 | Validation (Modify) | Covid-19 pre-exposure drugs, infection and vaccine questions must be answered | Questions disabled | |
| F4100 r9 | Q183-189 | Validation (Modify) | Covid-19 pre-exposure drugs and vaccine questions must be answered | Questions disabled | |
| F2003 r1 | Q13 and 20 | Validation (Modify) | Questions must be answered | If and only if Q1 = other, then Q13 and Q20 must be answered | Burden reduction |
| F2037 r3 | Q54 | Smart Navigation | If Q54 = normal, then go to Q57 | If Q54 = normal, then go to Q55 | Data quality improvement, gadolinium information being collected |
| Q55 | Validation (Modify) | If and only if Q54 = abnormal, then Q55 must be answered | If Q54 is answered, then Q55 must be answered | ||
| F2137 r3 | Q37 | Smart Navigation | If Q36 = normal, then go to Q39 | If Q36 is answered, then go to Q37 | Data quality improvement, gadolinium information being collected |
| Validation (Modify) | If and only if Q36 = abnormal, then Q37 must be answered | If Q36 is answered, then Q37 must be answered | |||
| F2100 r9 | Q140, 389, 390, 393, 395, 399 and 400 | Validation (Modify) | Question validations based on patient’s current age | Question validations based on patient’s age at date of contact reported on follow-up form | Data quality improvement, prevent errors if correcting old data |
| F2110 r4 | Q104 | Modify (Floating Text) | No floating text | Floating text added to indicate when each answer option should be selected | Eliminate reporting confusion |
| Validation (Add) | If Q51, Q63, Q70, Q80, Q87 = no, then Q104 must be no | ||||
| F2111 r4 | Q95 | Modify (Floating Text) | No floating text | Floating text added to indicate when each answer option should be selected | Eliminate reporting confusion |
| Validation (Add) | If Q48, Q54, Q61, Q71, Q78 = no, then Q95 must be no | ||||
| F2114 r4 | Q172 | Modify (Floating Text) | No floating text | Floating text added to indicate when each answer option should be selected | Eliminate reporting confusion |
| Validation (Add) | If Q88 = not answered or no or not applicable and Q94 = not answered or no and Q100, Q109, Q118, Q137, Q144, Q148 = no, then Q172 must be no | ||||
| F2157 r1 | Q203 | Modify (Floating Text) | No floating text | Floating text added to indicate when each answer option should be selected | Eliminate reporting confusion |
| Validation (Add) | If Q105 = no or not applicable and Q111, Q117, Q130, Q139, Q167, Q174, Q178 = no, then Q203 must be no |
March 2024 (released March 22nd, 2024)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F4006 r6 | Q33 | Validation (Add) | Q33 (Specify start date) must be between date of product infusion and date of product infusion +2 days. | Q33 (Specify start date) must be greater than or equal to event date | Allows for a broader date range to be reported |
| F2003 r1 | Q3-5 | Validation (Modify) | If and only if Q2 = Gene Therapy product ID, then Q3 must be answered. If and only if Q2 = Batch number, then Q4 must be answered. If and only if Q2 = Lot number, then Q5 must be answered. |
If Q2 contains Gene Therapy product ID, then Q3 must be answered. If Q2 contains Batch number, then Q4 must be answered. If Q2 contains Lot number, then Q5 must be answered. |
Fixing previously incorrect validations to work as initially intended |
February 2024 (released February 23rd, 2024)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2402 r7 | Q415 | Validation (Modify) | If Q413 is multiple myeloma then Q415 may contain any combination of heavy and light chain options | If and only if Q413 is answered as multiple myeloma then Q415 must contain only heavy chain OR only light chain options. Will receive error if both heavy and light chain options are reported together | Prevent contradicting information from being reported |
| F2100 r9 | Q121 and 191 | Modify (Floating Text) | Brand names listed next to drug options | Brand names no longer listed next to drug options. Only generic drug names are listed on form | Eliminate reporting confusion |
January 2024 (released January 26th, 2024)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2402 r7 | Q469-501 | Validation (Modify) | Q469-501 are required for Thalassemia | Q469-501 will still be required for Thalassemia. Q469-474, 477-494 & 499-501 will be answered for Sickle Cell Disease | These questions will now be required for both Thalassemia and Sickle Cell Disease (previously only required for Thalassemia) |
| F2030 r3 | Q28-29, 38-40, 41-46 | Validation (Modify) | If Q27 = yes, then Q28 must be answered. Q38 & Q41 must be answered |
Q28, 38 & 41 no longer need to be answered | Because these questions are now answered on F2402 (see above revision), they will be disabled on F2030 to avoid duplicate reporting |
| F2402 r7 | Q93-101, 169-177 | Validation (Modify) | MRD questions are disabled | MRD questions are enabled AML: Q93-95 & 99-101 ALL: Q169-171 & 175-177 |
For AML and ALL, these MRD questions are now required to be answered |
December 2023 (released December 8th, 2023)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2100 r9 | Q209-211 | Validation (Add) | Questions required only for recipients with acute or chronic GVHD | Questions required for all ALLO recipients regardless of GVHD status | Information required for all ALLO patients |
| F2100 r9 | Q348-349 | Validation (Modify) | Active questions | Inactive questions | No longer collecting data Note: If questions were previously answered, data will be removed from form |
| F2116 r5 | Q110-141 | Validation (Add) | If Q4 = yes, must answer Q110-141 | Will not need to re-answer Q110-141 | Burden reduction |
| F2116 r5 | Q228 and Q230 | Validation (Modify) | Questions must always be answered | If Q1 = AMYL or MRGS OR Q2 contains AMYL or MGRS, then Q228 and 230 must be answered | Only captured at baseline for AMYL or MGRS and should only be captured for same diseases at follow-up Note: If questions were previously answered for data that is not AMYL or MGRS, data will be removed from form |
| F2014/2114, F2016, F2028/2128, F2057/2157 | Validation (Modify) | Karyotype ISCN string field does not exist | Karyotype ISCN string field added | Expanding functionality |
November 2023 (released November 17th, 2023)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2100 r9 | Q317 | Validation (Modify) | If cardiac impairment/disorder = arrhythmia or pericarditis, then Q317 must be answered | If cardiac impairment/disorder = arrhythmia, pericarditis or cardiomyopathy, then Q317 must be answered | Cardiomyopathy has been added as a cardiac impairment/disorder that, when reported, makes Q317 required |
| F2402 r7 | Q92 & Q168 | Validation (Modify) | If disease status = 1CR, 2CR, or GE3CR, then number of cycles of induction therapy required to achieve 1st CR must be answered | If disease status = 1CR, then number of cycles of induction therapy required to achieve 1st CR must be answered | A disease status that is anything but 1CR implies the disease is more aggressive. Thus, only patients in 1CR should have this question answered |
| F2116 r5 | Q30 | Validation (Modify) | If Q1 = amyloidosis, MGRS or other PCD OR Q2 contains amyloidosis or MGRS, then Q30 must be answered If Q4 or Q7 = no, then Q30 must be answered |
If Q1 = MGRS or Q2 contains MGRS and Q4 = no OR Q1 = amyloidosis or Q2 contains amyloidosis and Q7 = no, then Q30 must be answered | Previous validations were combined into a single validation to prevent contradicting validations and incorrect errors occurring for users |
| F2116 r5 | Q32 | Validation (Modify) | If Q1 = amyloidosis, MGRS, other PCD OR Q2 = amyloidosis or MGRS, then Q32 must be answered If Q4 or Q7 = no, then Q32 must be answered |
If Q1 = MGRS or Q2 contains MGRS and Q4 = no OR Q1 = amyloidosis or Q2 contains amyloidosis and Q7 = no, then Q32 must be answered | Previous validations were combined into a single validation to prevent contradicting validations and incorrect errors occurring for users |
| F2400 r10 | Q61 | Validation (Modify) | If Q45 contains single cord blood unit or Q44 = allogeneic, unrelated and Q55 is not answered, then Q61 must be answered | If Q45 contains single cord blood unit and Q53 = no OR Q44 = allogeneic, unrelated and Q45 contains any (BM, PBSC, Other) and Q55 is not answered, then Q61 must be answered | Cord blood units facilitated through NMDP are not required to answer the Cord Blood Bank, this question is now optional. Note: optional fields will appear enabled, but there will not be a validation error if it is left blank |
October 2023 (released October 27, 2023)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2402 r6 | Q18, 45, 72, 110, 129, 148, 213, 250, 301, 358, 436 |
Validation (Add) | ISCN validations do not exist | ISCN validations added | Support AGNIS centers using 2402r6 |
September 2023 (released September 22, 2023)
No updates to communicate.
August 2023 (released August 25, 2023)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2100 r7-8 F2149 r1 F2900 r4-5 F4100 r5-9 |
Events and Actions | If COVID-19 (SARS-CoV-2) infection is reported F2149 comes due | F2149 will not come due | Data no longer being collected except for BMT CTN 2101 study | |
| F2149 r1 | Events and Actions | On-demand capability enabled | On-demand capability removed, CIBMTR will add form manually | Data no longer being collected except for BMT CTN 2101 study |
July 2023 (released July 28, 2023)
| Form_Revision | Question | Type of Change | Current | New | Rationale for Change |
|---|---|---|---|---|---|
| F2000 r6 | Q115 | Validation (Modify) | If country of primary residence is EQUAL to any (AS, GU, MP, PR, US, UM, VI) then household income must be answered | Household income question will be disabled for all | To coincide with cell therapy form updates and reduce reporting burden |
| F4000, F4100, F4003, F4006, F4101 | Option group (add and modify) | Afamitresgene autoleucel added to cell therapy product list and Orvacabtagene autoleucel removed from cell therapy product list | Changes in availability/production of cell therapy products | ||
| F2400 r10 | Q19 | Option group (add) | Four COG studies added to the dropdown list. These include: COG AALL1732, COG AAML1831, COG APAL2020SC (PedAL) and COG ASCT2031 | Updating list to include additional studies | |
| F2400 r10 and F4000 r10 | Q17 (F2400) and Q9 (F4000) | Option group (modify) | Study sponsor list includes “RCI BMT” | “RCI BMT” has been changed to “CIBMTR CRO Services” | Change in sponsor name |
| F2400 r10 and 2003 r1 | Q79 (2400) and Q1 (2003) | Option group (add) | Only option for gene therapy product name is “other name” | New options for gene therapy products added. Product options include: Betibeglogene autotemcel (Zynteglo®), Elivaldogene autotemcel (Skysona®), Exagamglogene autotemcel and Other name (specify) | Updating list to add gene therapy product names |
Last modified:
Aug 23, 2024